Yejing Zhu
-
- Signaling Pathways in Disease 2
-
- Ferroptosis and cancer prognosis 2
-
- Cancer Immunotherapy and Biomarkers 3
-
- Nanoplatforms for cancer theranostics 3
-
- Hepatocellular Carcinoma Treatment and Prognosis 2
- Liver Disease and Transplantation 2
-
- Liver Disease Diagnosis and Treatment 2
-
- COVID-19 Clinical Research Studies 2
- Co-authors
- Hua LiGeng XuShoujie ZhaoLei LiuJinyu ChiJunlong ZhaoJie HuDayun Feng
- Cited by
- Cancer ResearchImmunologyPhysiology
- Partner nations
- ChinaUnited States
In The Last Decade
Yejing Zhu
17 papers receiving 325 citations
Peers
Comparison fields: 5 of 73
- Cancer Research 85
- Immunology 58
- Physiology 10
- Molecular Biology 146
- Pulmonary and Respiratory Medicine 49
Countries citing papers authored by Yejing Zhu
This map shows the geographic impact of Yejing Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yejing Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yejing Zhu more than expected).
Fields of papers citing papers by Yejing Zhu
This network shows the impact of papers produced by Yejing Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yejing Zhu. The network helps show where Yejing Zhu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yejing Zhu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 3 | |
| 5 | 2024 | 1 | |
| 6 | 2023 | 7 | |
| 7 | 2023 | 8 | |
| 8 | 2023 | 3 | |
| 9 | 2022 | 2 | |
| 10 | 2022 | 53 | |
| 11 | 2021 | 2 | |
| 12 | 2021 | 84 | |
| 13 | 2021 | 1 | |
| 14 | 2021 | 7 | |
| 15 | 2020 | 66 | |
| 16 | 2012 | 16 | |
| 17 | 2012 | 37 | |
| 18 | 2012 | 13 | |
| 19 | Cyclosporin A induces cardiomyocyte injury through calcium-sensing receptor-mediated calcium overload. | 2011 | 22 |
About Yejing Zhu
Yejing Zhu is a scholar working on Hepatology, Physiology and Oncology, having authored 19 papers that have together received 326 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (3 papers), Nanoplatforms for cancer theranostics (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Liver Disease Diagnosis and Treatment (2 papers), COVID-19 Clinical Research Studies (2 papers), Ferroptosis and cancer prognosis (2 papers), Liver Disease and Transplantation (2 papers) and Signaling Pathways in Disease (2 papers). The work is most often cited by research in Cancer Research (85 citations), Immunology (58 citations) and Physiology (10 citations). Yejing Zhu has collaborated with scholars based in China and United States. Frequent co-authors include Hua Li, Geng Xu, Shoujie Zhao, Lei Liu, Jinyu Chi, Junlong Zhao, Jie Hu, Dayun Feng, Xinhua Yin and Enxin Wang. Their work appears in journals such as Small, Molecular Cancer and Advanced Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.